8 recruiting, 3 active not recruiting, 3 terminated, 2 completed. 14 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Recruiting 7, Active not recruiting 3, Terminated 2, Completed 1, Withdrawn 1 |
| Phase 2 | 10 | Recruiting 3, Terminated 3, Active not recruiting 2, Completed 2 |
Follow Recurrent Chronic Myelomonocytic Leukemia: new trials by email Literature Review of Recurrent Chronic Myelomonocytic Leukemia trials Research Report on Recurrent Chronic Myelomonocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Onvansertib - Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 25 | 2023-04-04 | 2026-06-22 |
| Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Azacitidine, Seclidemstat - Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1 | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 24 | 2021-07-07 | 2026-09-18 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia Cladribine, Cyclophosphamide, Cyclosporine - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 120 | 2020-12-03 | 2026-09-17 |
| Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Azacitidine, Venetoclax - Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 34 | 2020-09-04 | 2026-06-05 |
| A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Canakinumab - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 76 | 2020-08-25 | 2026-05-20 |
| Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome Azacitidine, Trametinib, Venetoclax - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 21 | 2020-07-21 | 2025-04-22 |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Azacitidine, Quizartinib - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2020-07-21 | 2026-10-05 |
| Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Rivogenlecleucel, Rimiducid - Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2020-01-02 | 2020-08-14 | |
| Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm Azacitidine, Gilteritinib, Venetoclax - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 97 | 2019-12-17 | 2026-10-06 |
| CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Liposome-encapsulated Daunorubicin-Cytarabine - Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 38 | 2019-05-14 | 2026-10-06 |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 72 | 2019-01-31 | 2026-09-18 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2018-02-23 | 2026-05-18 |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome Decitabine, Laboratory Biomarker Analysis, Venetoclax - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Terminated | M.D. Anderson Cancer Center | 235 | 2018-01-18 | 2026-03-10 |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Azacitidine, Cytarabine, Quizartinib - FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 73 | 2013-11-12 | 2026-10-23 |
Leukemia, Myelomonocytic, Chronic (17) · Myelodysplastic Syndromes (13) · Leukemia, Myeloid, Acute (10) · Leukemia, Biphenotypic, Acute (5) · Blastic Plasmacytoid Dendritic Cell Neoplasm (4) · Myelodysplastic-Myeloproliferative Diseases (3) · Myeloproliferative Disorders (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Blast Crisis (2) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Primary Myelofibrosis (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Erdheim-Chester Disease (1)
Bone Marrow Diseases (17) · Chronic Disease (17) · Disease Attributes (17) · Hematologic Diseases (17) · Hemic and Lymphatic Diseases (17) · Leukemia, Myeloid (17) · Neoplasms (17) · Neoplasms by Histologic Type (17) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17) · Leukemia (16) · Myelodysplastic-Myeloproliferative Diseases (14) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Leukemia, Lymphoid (7)
Azacitidine (7) · Cytarabine (5) · venetoclax (5) · Biopsy (3) · Filgrastim (3) · Granulocyte Colony-Stimulating Factor (3) · Injections (3) · Specimen Handling (3) · Cyclophosphamide (2) · Decitabine (2) · Hematopoietic Stem Cell Transplantation (2) · Idarubicin (2) · Stem Cell Transplantation (2) · Whole-Body Irradiation (2) · X-Rays (2)
M.D. Anderson Cancer Center (11) · Fred Hutchinson Cancer Center (4) · Mayo Clinic (2)
United States (17)
Guillermo M Bravo (3) · Elizabeth Krakow (2) · Guillermo Garcia-Manero (2) · Nicholas Short (2) · Abhishek Maiti, MBBS (1) · Filippo Milano (1) · Jithma P. Abeykoon, MD (1) · Mrinal S. Patnaik, MBBS (1) · Naval G Daver, MD (1) · Naveed Ali, MD (1) · Tapan M Kadia (1) · Yesid Alvarado, MD (1)
PMID 32896301, PMID 33027528, PMID 33580980, PMID 33792630, PMID 34255353, PMID 34474640, PMID 36841758, PMID 37946611, PMID 38277619, PMID 38683966, PMID 38744144, PMID 39537648, PMID 42200455
P30CA015704 (2), P50CA100632 (1), R01CA272496 (1)